Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,902,750
  • Shares Outstanding, K 73,750
  • Annual Sales, $ 105,970 K
  • Annual Income, $ -81,130 K
  • EBIT $ -93 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.20
  • Price/Sales 18.05
  • Price/Cash Flow N/A
  • Price/Book 7.23

Options Overview Details

View History
  • Implied Volatility 73.03% (-4.42%)
  • Historical Volatility 44.66%
  • IV Percentile 12%
  • IV Rank 14.75%
  • IV High 220.79% on 11/14/25
  • IV Low 47.46% on 08/22/25
  • Expected Move (DTE 12) 1.96 (7.58%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 45
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 5,827
  • Open Int (30-Day) 6,366
  • Expected Range 23.85 to 27.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 6
  • High Estimate $1.08
  • Low Estimate $-0.52
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.43 +15.02%
on 03/13/26
28.00 -7.86%
on 03/10/26
+2.49 (+10.68%)
since 03/02/26
3-Month
21.93 +17.65%
on 02/23/26
28.00 -7.86%
on 03/10/26
-0.82 (-3.08%)
since 01/02/26
52-Week
9.03 +185.71%
on 04/10/25
28.49 -9.44%
on 11/26/25
+13.88 (+116.44%)
since 04/02/25

Most Recent Stories

More News
Zymeworks Appoints Kristin Stafford as Chief Financial Officer

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...

ZYME : 25.80 (-0.54%)
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer...

ZYME : 25.80 (-0.54%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...

ZYME : 25.80 (-0.54%)
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 25.80 (-0.54%)
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR ⍺ )-targeting...

ZYME : 25.80 (-0.54%)
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 48.57 (+0.16%)
ZYME : 25.80 (-0.54%)
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 48.57 (+0.16%)
ZYME : 25.80 (-0.54%)
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026...

ZYME : 25.80 (-0.54%)
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

ZYME : 25.80 (-0.54%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

ZYME : 25.80 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 27.73
2nd Resistance Point 27.23
1st Resistance Point 26.51
Last Price 25.80
1st Support Level 25.29
2nd Support Level 24.79
3rd Support Level 24.07

See More

52-Week High 28.49
Last Price 25.80
Fibonacci 61.8% 21.06
Fibonacci 50% 18.76
Fibonacci 38.2% 16.46
52-Week Low 9.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.